Intuitive Surgical, Inc. (ISRG) Return on Invested Capital (ROIC): 13.71%
Is Intuitive Surgical, Inc.’s return on invested capital (ROIC) high or low?
Intuitive Surgical, Inc.'s return on invested capital (ROIC) of 13.71% is 15% above its 5-year average of 11.92%, near the high end of its 5-year range (9.09%–13.71%).
The return on invested capital (ROIC) for Intuitive Surgical, Inc. (ISRG) is 13.71% as of Wednesday, June 10, 2026. It is above its 12-month average by 6.69% (12.85%).
ISRG Return on Invested Capital (ROIC) Chart
ISRG Average Return on Invested Capital (ROIC) Chart
ISRG Current vs Average Return on Invested Capital (ROIC) Chart
ISRG Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
13.71%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
12.85%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
12.25%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
11.92%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
12.73%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
14.09%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
14.03%
CURRENT VS TTM AVG
+6.69%
CURRENT VS 3Y AVG
+11.90%
CURRENT VS 5Y AVG
+15.02%
CURRENT VS 10Y AVG
+7.68%
CURRENT VS 15Y AVG
-2.69%
CURRENT VS 20Y AVG
-2.26%
ISRG Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 13.71% | 12.85% | 12.25% | 11.92% |
| Pfizer Inc. (PFE) | $146.36B | 8.84% | 9.06% | 10.60% | 10.43% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 21.53% | 11.95% | 11.58% | 9.92% |
| Abbott Laboratories (ABT) | $154.66B | 8.43% | 9.16% | 9.70% | 9.86% |
| Danaher Corporation (DHR) | $130.25B | 5.72% | 5.90% | 6.54% | 6.70% |
| CVS Health Corporation (CVS) | $125.16B | 4.72% | 4.17% | 4.46% | 4.93% |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 13.90% | 13.75% | 11.92% | 10.17% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 7.58% | 7.80% | 8.16% | 9.10% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 18.12% | 10.38% | 14.75% | 17.51% |
| Amgen Inc. (AMGN) | $183.75B | 13.16% | 11.04% | 11.80% | 12.80% |
Capital Efficiency
ROIC
13.7%
ROE
17.1%
Intuitive Surgical, Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Intuitive Surgical, Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Intuitive Surgical, Inc. (ISRG)?
- The return on invested capital (ROIC) for ISRG stock is 13.71%.
- Is Intuitive Surgical, Inc.'s return on invested capital (ROIC) high or low?
- Intuitive Surgical, Inc.'s return on invested capital (ROIC) of 13.71% is 15% above its 5-year average of 11.92%, near the high end of its 5-year range (9.09%–13.71%).
- What is the TTM average return on invested capital (ROIC) for Intuitive Surgical, Inc. (ISRG)?
- The TTM average return on invested capital (ROIC) for ISRG stock is 12.85%.
- What is the 3Y average return on invested capital (ROIC) for Intuitive Surgical, Inc. (ISRG)?
- The 3Y average return on invested capital (ROIC) for ISRG stock is 12.25%.
- What is the 5Y average return on invested capital (ROIC) for Intuitive Surgical, Inc. (ISRG)?
- The 5Y average return on invested capital (ROIC) for ISRG stock is 11.92%.
- What is the 10Y average return on invested capital (ROIC) for Intuitive Surgical, Inc. (ISRG)?
- The 10Y average return on invested capital (ROIC) for ISRG stock is 12.73%.
- What is the 15Y average return on invested capital (ROIC) for Intuitive Surgical, Inc. (ISRG)?
- The 15Y average return on invested capital (ROIC) for ISRG stock is 14.09%.
- What is the 20Y average return on invested capital (ROIC) for Intuitive Surgical, Inc. (ISRG)?
- The 20Y average return on invested capital (ROIC) for ISRG stock is 14.03%.
Intuitive Surgical, Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 13.71% |
| 2024-12-31 | 11.99% |
| 2023-12-31 | 11.89% |
| 2022-12-31 | 11.42% |
| 2021-12-31 | 13.42% |
| 2020-12-31 | 9.09% |
| 2019-12-31 | 14.53% |
| 2018-12-31 | 15.01% |
| 2017-12-31 | 13.43% |
| 2016-12-31 | 12.27% |
| 2015-12-31 | 13.30% |
| 2014-12-31 | 12.30% |
| 2013-12-31 | 18.40% |
| 2012-12-31 | 18.16% |
| 2011-12-31 | 18.32% |
| 2010-12-31 | 18.18% |
| 2009-12-31 | 14.42% |
| 2008-12-31 | 14.46% |
| 2007-12-31 | 13.87% |
| 2006-12-31 | 10.89% |
| 2005-12-31 | 15.50% |
| 2004-12-31 | 6.49% |
| 2003-12-31 | -4.22% |
| 2002-12-31 | -30.16% |
| 2001-12-31 | -20.69% |
| 2000-12-31 | -19.60% |
| 1999-12-31 | -74.19% |
| 1998-12-31 | 0.00% |
Related Metrics
About Intuitive Surgical, Inc.
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- David J. Rosa